| identifier: | 2114167 |
| description: |
epitope description:P75, E76, H79, Q107, P108, M110, K111, L112, G113, T114, Q115, T116, V117, P118, C119, T148, L150, R194, R195, F196, E198, A199, C201, E233, K234
antigen name:ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
host organism:Mus musculus
antibody name:SAR650984
|
| aggregation: |
instance of dataset
|
| availability: |
available
|
| primaryPublications: |
24987056 |
| authorizations: |
registration not required
|
| accessURL: |
http://www.iedb.org/reference/1027976 |
| landingPage: |
http://www.iedb.org/assay/2114167 |
| type: |
Literature
|
| publicationVenue: |
Clin Cancer Res
|
| dates: |
2014
|
| study type: | b cell assays |
| subject species: | Homo sapiens |
| fullName: |
Jutta Deckert
Marie-Cé
cile Wetzel
Laura M Bartle
Anna Skaletskaya
Victor S Goldmacher
Franç
ois Vallé
e
Qing Zhou-Liu
Paul Ferrari
Sté
phanie Pouzieux
Charlotte Lahoute
Charles Dumontet
Adriana Plesa
Marielle Chiron
Pascale Lejeune
Thomas Chittenden
Peter U Park
Vé
ronique Blanc
|
| method: |
biological activity
|
| name: |
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
|
| description: |
The epitope residues were calculated from [PDB: 4CMH] as the antigen residues at 4Å
atomic distance from the antibody.
The epitope-specific SAR650984 antibody bound to CD38 on Raji, Daudi or Ramos lymphoma cells and other cell lines and displayed pro-apoptotic activity in the absence of cross-linking agents, as determined by Annexin V-positive staining and cell lysis. SAR650984 also induced apoptosis without added cross-linking agents in primary cells isolated from bone marrow of multiple myeloma patients.
|
| name: |
iedb
|
| homePage: |
http://www.iedb.org |